Goldman Sachs Group Inc. is leading a $3.75 billion debt deal to fund Arclin Inc.’s acquisition of DuPont de Nemours Inc.’s Aramids business, according to people familiar with the matter.
The lender is weighing investor interest for a deal comprising a $3 billion term loan and a $250 million delayed-draw term loan, said the people familiar with the transaction, who requested anonymity to discuss a private transaction. The financing will also include a $500 million revolving credit facility, said one of the people.